First estimates of diffuse gastric cancer risks for carriers of


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
12 2022
Historique:
received: 03 06 2022
accepted: 02 08 2022
pubmed: 30 8 2022
medline: 25 11 2022
entrez: 29 8 2022
Statut: ppublish

Résumé

Pathogenic variants (PV) of Data from published CTNNA1 families were updated and new families were identified through international collaborations. The cumulative risk of DGC by age for PV carriers was estimated with the genotype restricted likelihood (GRL) method, taking into account non-genotyped individuals and conditioning on all observed phenotypes and genotypes of the index case to obtain unbiased estimates. A non-parametric (NP) and the Weibull functions were used to model the shape of penetrance function with the GRL. Kaplan-Meier incidence curve and standardised incidence ratios were also computed. A 'leave-one-out' strategy was used to evaluate estimate uncertainty. Thirteen families with 46 carriers of PV were included. The cumulative risks of DGC at 80 years for carriers of This is the largest series of

Sections du résumé

BACKGROUND
Pathogenic variants (PV) of
METHODS
Data from published CTNNA1 families were updated and new families were identified through international collaborations. The cumulative risk of DGC by age for PV carriers was estimated with the genotype restricted likelihood (GRL) method, taking into account non-genotyped individuals and conditioning on all observed phenotypes and genotypes of the index case to obtain unbiased estimates. A non-parametric (NP) and the Weibull functions were used to model the shape of penetrance function with the GRL. Kaplan-Meier incidence curve and standardised incidence ratios were also computed. A 'leave-one-out' strategy was used to evaluate estimate uncertainty.
RESULTS
Thirteen families with 46 carriers of PV were included. The cumulative risks of DGC at 80 years for carriers of
CONCLUSION
This is the largest series of

Identifiants

pubmed: 36038258
pii: jmg-2022-108740
doi: 10.1136/jmg-2022-108740
doi:

Substances chimiques

Cadherins 0
CTNNA1 protein, human 0
alpha Catenin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1189-1195

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Marie Coudert (M)

Département de Génétique, Institut Curie, Paris, France.

Youenn Drouet (Y)

CNRS UMR 5558 LBBE, Université de Lyon, Villeurbanne, France.
Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.

Hélène Delhomelle (H)

Département de Génétique, Institut Curie, Paris, France.

Magali Svrcek (M)

AP-HP, Saint-Antoine Hospital, Department of Pathology, Sorbonne Université, Paris, France.

Patrick R Benusiglio (PR)

Département de Génétique Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.

Florence Coulet (F)

Département de Génétique Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.

Dana Farengo Clark (DF)

Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Bryson W Katona (BW)

Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Liselotte P van Hest (LP)

Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Lizet E van der Kolk (LE)

Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Annemieke Cats (A)

Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jolanda M van Dieren (JM)

Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Bita Nehoray (B)

Division of Clinical Cancer Genomics, City of Hope, Duarte, California, USA.

Thomas Slavin (T)

Departments of Medical Oncology and Population Sciences, City of Hope, Duarte, California, USA.

Isabel Spier (I)

Institute of Human Genetics/National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Robert Hüneburg (R)

Department of Internal Medicine/National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.

Silvana Lobo (S)

IPATIMUP-Institut of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
i3s, Universidade do Porto Instituto de Investigação e Inovação em Saúde, Porto, Portugal.

Carla Oliveira (C)

Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
Faculty of Medicine, University of Porto, Porto, Portugal.

Lise Boussemart (L)

Service de Dermatologie, Hotel Dieu, Nantes, France.

Laure Masson (L)

Dermatologie, CHU Rennes, Rennes, France.

Jean Chiesa (J)

Génétique, Hopital Universitaire Caremeau, Nimes, France.

Mathias Schwartz (M)

Département de Génétique, Institut Curie, Paris, France.

Bruno Buecher (B)

Département de Génétique, Institut Curie, Paris, France.

Lisa Golmard (L)

Département de Génétique, Institut Curie, Paris, France.

Anne-Marie Bouvier (AM)

Digestive Cancer Registry of Burgundy, UMR 1231, Réseau FRANCIM (réseau Français des registres du cancer), Burgundy Franche-Comté University, Dijon, France.

Valérie Bonadona (V)

CNRS UMR 5558 LBBE, Université de Lyon, Villeurbanne, France.
Unité Clinique d'Oncologie génétique, Centre Leon Berard, Lyon, France.

Dominique Stoppa-Lyonnet (D)

Département de Génétique, Institut Curie, Paris, France.
INSERM U830, Université de Paris, Paris, France.

Christine Lasset (C)

CNRS UMR 5558 LBBE, Université de Lyon, Villeurbanne, France.
Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.

Chrystelle Colas (C)

Département de Génétique, Institut Curie, Paris, France chrystelle.colas@curie.fr.
INSERM U830, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH